Sun, Dec 28, 2014, 11:21 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • biglabowski99 biglabowski99 Jul 14, 2013 9:05 AM Flag

    Scientists Refine and Develop New Strategies to Target Bone Metastases

    ran across this article, google title above

    Another agent, called cabozantinib, “has had a spectacular result” in a phase II randomized trial of advanced prostate cancer patients, says Smith, who took part in the study. The phase III COMET-1 is currently testing the oral targeted agent in men with CRPC who have already been treated with the FDA-approved androgen-receptor pathway agents abiraterone acetate and enzalutamide.

    Cabozantinib inhibits the MET tyrosine kinase as well as vascular endothelial growth factor receptor 2 (VEGFR2). Seventy-two percent of the 171 men in the phase II trial had tumor shrinkage in areas excluding the bone and 68% had improvements in bone metastases. The striking improvements in patients’ bone scans haven’t been seen before, Smith says. Patients also had relief from the pain associated with these metastases—67% showed improvement in pain.

    “The bone metastases improvement was unexpected, but it is explainable,” Smith says. VEGFR is involved in bone remodeling, prostate tumor growth, and tumor-bone interaction.

1.33+0.04(+3.10%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.